U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Zanubrutinib (Brukinsa): CADTH Reimbursement Review: Therapeutic area: Chronic lymphocytic leukemia [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov.

Cover of Zanubrutinib (Brukinsa)

Zanubrutinib (Brukinsa): CADTH Reimbursement Review: Therapeutic area: Chronic lymphocytic leukemia [Internet].

Show details
The horizontal axis indicates the number of patients who experienced any recurrence of BTK inhibitor intolerance. The vertical axis indicates types of intolerance events experienced by patients who had previously taken either ibrutinib or acalabrutinib. Horizontal bars indicate numbers of patients that fall into each category of intolerance event. These bars are coloured with blue to represent no recurrence, green to represent recurrence at a lower grade, yellow to indicate recurrence at same grade, and red to mark recurrence at higher grade. Among patients who had previously taken ibrutinib, up to 8 patients in each category of adverse event are represented by the colour blue, meaning they did not experience any recurrence of fatigue, hypertension, rash, atrial fibrillation, arthralgia, stomatitis, muscle spasms, hemorrhage, myalgia, headache, constipation, lymphoedema, AST and ALT increase, pain in extremity, neutropenia, and nausea .Among patients who had previously taken acalabrutinib, 3 patients are indicated by a blue bar, meaning they did not experience recurrence of arthralgia, and 1 patient was also represented as a blue bar, meaning they did not experience recurrence of myalgia. In both cohorts, some intolerance events recurred and are green for a lower grade and yellow for the same grade. None of the bar graphs is red, meaning none of the intolerance events recurred at a higher grade.

Figure 20Recurrence of BTK Intolerance Events in Patients on Zanubrutinib in Study 215 (Data Cut-Off Date of September 8, 2021)

Source: Sponsor Summary of Clinical Evidence.4

ALT = alanine aminotransferase; AST = aspartate aminotransferase; BTK = Bruton tyrosine kinase.

a Eighteen ibrutinib intolerance events (arthritis, bone pain, bronchitis, embolism, irregular heart rate, malaise, pericardial effusion, pleural effusion, pneumonia, psoriasis, pyrexia, sinusitis, subcutaneous abscess, supraventricular tachycardia, increased transaminases, ventricular extrasystoles, vertigo, and vomiting) occurred in 1 patient and did not recur on zanubrutinib.

b Eleven acalabrutinib intolerance events (abdominal pain, asthenia, atrial fibrillation, dyspepsia, fatigue, groin pain, headache, insomnia, malaise, pain in extremity, and rash) occurred in 1 patient and did not recur on zanubrutinib (not shown in Figure 3).

From: Clinical Review

Copyright Notice

Copyright © 2023 - Canadian Agency for Drugs and Technologies in Health. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND).

Contents

Views

  • Cite this Page
  • PDF version of this title (18M)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...